Efficacy and safety of vardenafil for kidney transplant recipients with erectile dysfunction / 中华男科学杂志
National Journal of Andrology
; (12): 911-913, 2008.
Article
en Zh
| WPRIM
| ID: wpr-309749
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of vardenafil in kidney transplant recipients with erectile dysfunction.</p><p><b>METHODS</b>Thirty-nine kidney transplant recipients with erectile dysfunction (ED) and serum creatinine values <2 mg/dl were enrolled in a 4-week randomized, double blind, placebo-controlled study, 19 treated with placebo and 20 with vardenafil. Vardenafil efficacy was assessed with the IIEF questionnaire after 4 weeks of treatment, and its safety appraised by measuring serum creatinine levels, creatinine clearances and cyclosporine concentrations before and after the treatment.</p><p><b>RESULTS</b>IIEF scores improved from 12.6 +/- 3.4 to 26.5 +/- 2.8 (P < 0.01), but renal function and cyclosporine concentrations remained unchanged in the vardenafil-treated patients. Adverse effects were observed in 4 patients: headache in 2, palpitation and flush in 1, and dyspepsia in the other.</p><p><b>CONCLUSION</b>Oral vardenafil therapy has a high efficacy and a low incidence of adverse events for kidney transplant recipients with ED.</p>
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Inhibidores de Fosfodiesterasa
/
Piperazinas
/
Sulfonas
/
Triazinas
/
Método Doble Ciego
/
Diálisis Renal
/
Trasplante de Riñón
/
Usos Terapéuticos
/
Quimioterapia
/
Diclorhidrato de Vardenafil
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
/
Male
Idioma:
Zh
Revista:
National Journal of Andrology
Año:
2008
Tipo del documento:
Article